DETROIT--(BUSINESS WIRE)--Asterand plc (LSE: ATD) today announced that the U.S. Environmental Protection Agency (EPA) has expanded its collaboration and Phase II funding commitment with Asterand’s subsidiary BioSeek LLC. Under the EPA ToxCast™ screening program, BioSeek is employing its unique BioMAP® Systems human primary cell assay platform to predict the biological activity and potential toxicity of environmental and other chemicals on human health. The new agreement provides $696,000 in additional funding for BioSeek and adds a further 100 compounds to the more than 1000 environmental compounds, pesticides, failed pharmaceuticals, and nanomaterials already analyzed using BioMAP Systems in this ongoing effort.
